September 16, 2015 – – Locked-Out Locksmiths Provides Information On How To Maintain a Burglar Proof Residence

London, UK – It’s time to make sure the house is burglar proof. To help London residents out with this, Locked-out LockSmiths (www.lockedout-locksmiths.co.uk) has just published a new blog post authored by Brendan Connolly entitled ‘Keys to Burglary Prevention That your London Locksmith Should Tell You‘.

The article discusses what things to check and insure against burglary that many often overlook or just don’t think to check.

“Making your home an easy target in the first place should never be an option,” states Connolly. “Never take any chances when it comes to home security. Being too paranoid is far more helpful than being accommodating enough to let a burglar in without you being the wiser.”

Connolly’s advice is derived directly from his experience as a locksmith and from other professional locksmiths, specialising in both residential and business security. The article relates further how to check letter box security, especially if it’s located in the door, securing of doors, patio doors and windows and even French doors. Specifically, the article points out that the Metropolitan Police website suggests securing any French doors in a home by having ‘Both doors fitted with mortice rack bolts (bolts fitted within the door and operated internally by a threaded key). Having them be fitted at a 90 º angle to the grain of the wood, and using surface-mounted locking bolts (push to lock, key to open)’.

“A potential burglar can easily gain access to your home should he choose to stick his hand inside the box,” states Connolly. “A trusted locksmith like those at Locked-out Locksmiths can reinforce any type of door or window that might serve as a potential entryway for burglars.”

To read the article or for more information, visit www.lockedout-locksmiths.co.uk.

###

Contact Locked Out London:

Brendan Connolly
connolly1971@yahoo.co.uk
69 Chesterton Square, Pembroke Road, London W8 6PJ

ReleaseID: 60004126

September 16, 2015 – – BloodThinnerHelp.com reports today on one of the latest Xarelto lawsuit filings. Recently, a Texas woman filed a lawsuit against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, the pharmaceutical division of Johnson&Johnson, in the Eastern District of New York. She is alleging that the manufacturer’s failure to adequately warn doctors and patients about the real risks of Xarelto and their failure to perform sufficient safety tests on the drug led to her serious internal bleeding injuries. The full complaint can be found here and is filed under the federal court docket number 1:14-CV-04524.

In this case, the plaintiff was prescribed Xarelto by her doctor and began taking it to prevent blood clots that may be caused by atrial fibrillation, a heart condition. She was using Xarelto for five months when she experienced a severe internal bleeding event that left her seriously injured. The complaint does not specify the injuries sustained but it does note that the injuries she suffered are permanent and will require long term future care.

Xarelto was approved by the Food and Drug Administration, FDA, for released onto the United States market in 2011. Xarelto’s manufacturers pushed the drug as a convenient alternative to the traditional blood thinner Warfarin because of Xarelto’s ‘one size fits all’ dosage and lack of required blood monitoring. Advertisements for the drug were heavily published in medical journals and television commercials for the drug featured well known athletes and public figures. Xarelto was initially approved for usage in patients who suffered from atrial fibrillation, deep vein thrombosis, or who have recently undergone knee or hip replacement surgeries.

The problem with Xarelto is that there is no antidote to the anticoagulant effects of the drug which makes it especially dangerous. If a patient is taking Warfarin and experiences an internal bleeding emergency, a doctor can administer vitamin K to reverse the effects of the Warfarin and the blood will clot. If a patient is taking Xarelto and experiences an internal bleeding emergency, there is no way to stop the bleeding. Xarelto currently has two ‘black box’ warnings attached to it by the FDA. The black box warning is the most strict warning the FDA can assign to a drug short of recalling it.

“If the manufacturers of Xarelto did conceal information about the true dangers of the drug, they deserve to be brought to justice,” Xarelto attorney Marc Goldich said. “If you or a loved one feel that you have been harmed by Xarelto, contact us immediately.”

For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Marc Goldich
866-425-8902
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.

ReleaseID: 60004201

September 16, 2015 – – Recently, ZofranLegal.com announced that the fourth Massachusetts Zofran lawsuit had been filed. Three of the four lawsuits allege that the drug Zofran caused a cardiac defect in an unborn child, and the fourth alleges that the unborn child died in utero due to birth defects caused by exposure to Zofran.

Zofran is an anti-emetic drug that is manufactured by GlaxoSmithKline. Prior to receiving approval from the U.S. Food and Drug Administration in 1991, GSK conducted multiple studies to determine the level of safety associated with using the drug. However, none of these studies were performed on pregnant women. As a result, the FDA only approved the drug for use in patients experiencing nausea and vomiting after chemotherapy and radiation treatments, or who were ill after being under anesthesia. Zofran was not awarded approval for the treatment of morning sickness.

Regardless of the absence of approval, GSK moved forward with a marketing campaign that promoted the use of Zofran “off-label” to treat morning sickness. Countless expectant mothers were prescribed the drug throughout their pregnancy. Since they first marketed the drug in this manner, GSK has allegedly received over 200 reports of children being born with birth defects after the mothers took Zofran.

The first Zofran lawsuit was filed in the U.S. District Court for the District of Massachusetts on February 16th, 2015 under case number 1:15-cv-10429. The lawsuit alleges that a girl born in 2000 was born with numerous congenital defects after her mother began taking Zofran during her 1st trimester. The worst of these defects is an atrial septal defect of the heart. The lawsuit states that “In twelve years, the child has had to undergo ten surgeries to try and correct her numerous congenital abnormalities. These birth defects impair her development and enjoyment of a normal life at home and at school due to substantial developmental delays.”

The second Massachusetts complaint was filed in April 2105, under case number 1:15-11627. It alleges that because the plaintiff took Zofran, her unborn child was diagnosed with severe physical malformations which were life-threatening. These malformations resulted in the death of her child in utero. The complaint further alleges that “Had the plaintiff and/or her healthcare providers known of the increased risk of birth defects associated with Zofran, she would not have taken Zofran during pregnancy, and her pregnancy would have progressed to term with a healthy child.”

A few months later, on July 22nd, 2015, the third lawsuit was filed under case number 1:15-cv-13002-FDS. Like the first two complaints, the mother claims that she was not warned of the risks associated with the use of Zofran during her pregnancy and that “GSK’s conduct has caused devastating, irreversible, and life-long consequences and suffering to innocent newborns and their families.” Her daughter was born with a cardiac defect known as the Transposition of the Greater Vessels (TGV) and she required life-saving surgery just days after she was delivered.

The latest Zofran lawsuit in Massachusetts was filed on July 17th, 2015 under case number 1:15-cv-12973. The child, in this case, was born in 2007. Shortly after his birth he was found to have a congenital heart defect called a ventricular septal defect and a systolic ejection heart murmur.

These lawsuits are following a complaint that was filed by the U.S. Justice Department against GSK. That complaint alleged that GSK had unlawfully marketed several drugs, including Zofran, “off-label”. In a settlement agreed upon in 2012, GSK paid fines of three billion dollars.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60004202

September 16, 2015 – – Tracey & Fox have commented on the U.S. Government Accountability Office’s decision to move forward with an investigation into the controversy stemming from the use of power morcellators during hysterectomies and myomectomies. Mr. Tracey has stated, “I welcome this investigation by the U.S. Government Accountability Office. It is tragic that so many women have lost their lives as a result of the use of this device. If the U.S. Food and Drug Administration’s approval process is improved because of continued scrutiny, only good things will come as a result.”

Mr. Gene Dodaro, the Comptroller General and the head of the GAO, received a letter on August 7th, 2015 from the United States Congress. The letter was a request for the GAO to begin an investigation into the manner through which the U.S. Food and Drug Administration granted approval for the medical device known as a power morcellator. It was signed by twelve members of Congress.

The letter stated that “hundreds, if not thousands, of women in America are dead” because of the use of power morcellators during gynecological surgeries.

The morcellator has been used by surgeons for decades in a wide variety of laparoscopic surgeries. It was first approved by the FDA under a 501(k), which allows the approval of a surgical device without safety testing, if the device can be shown to be “substantially equivalent” to a previously approved device. But on April 17th, 2014, the FDA released a safety communication which warned that “When used for hysterectomy or myomectomy in women with uterine fibroids, laparoscopic power morcellation poses a risk of spreading unsuspected cancerous tissue, notably uterine sarcomas, beyond the uterus.”

In an updated safety communication issued on November 24th, 2014, the FDA required all power morcellators to have a “black box” label, warning of the risks associated with its use.

On September 1st, 2015, the GAO responded to the lead member of the Congressional group, U.S. Rep. Mike Fitzpatrick, agreeing to accept the request. Katherine Siggerud, the managing director for congressional relations at the GAO, has indicated the investigation will begin in several months after the necessary staff are made available.

This announcement comes after speculation that the Federal Bureau of Investigations had begun their own investigation into the risks of the power morcellator, and numerous lawsuits have been filed by women and the families of women who all allege that undiagnosed uterine cancer was spread by a morcellator resulting in metastasis to other areas of the body.

For more information regarding this press release, call Tracey & Fox at (713) 322-5375.

###

Contact Tracey & Fox:

Sean Tracey
713-495-2333
440 Louisiana Street , Suite 1901
Houston, TX 77002

ReleaseID: 60004203